Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 557 entries
Sorted by: Best Match Show Resources per page
… of Osteopontin11Grant 12078 from the Canadian Breast Cancer Research Initiative (AFC and ABT) ALA is supported by the HL Holmes Postdoctoral Award from the …

postdoctoral

Allan AL.
GSID: H7U7pfB--dEJ
KA Furger, AL Allan, SM Wilson, C Hota… - Molecular Cancer …, 2003 - AACR

Osteopontin (OPN) is a secreted phosphoprotein that has been associated with malignancy of breast and other cancers. OPN binds to several cell surface integrins including α v β 3 , α …

Cite
Furger, K. A., Allan, A. L., Wilson, S. M., Hota, C., Vantyghem, S. A., Postenka, C. O., ... & Tuck, A. B. (2003). β3 Integrin Expression Increases Breast Carcinoma Cell Responsiveness to the Malignancy-Enhancing Effects of Osteopontin11Grant 12078 from the Canadian Breast Cancer Research Initiative (AFC and ABT) ALA is supported by the HL Holmes Postdoctoral Award from the National Research Council of Canada. SAV is supported by a predoctoral award from the US Medical Research and Material Command Breast Cancer Research Program. This work was performed in partial fulfillment of the requirement for the M. Sc. degree .... Molecular Cancer Research, 1(11), 810-819.
Furger, Kara A., et al. "β3 Integrin Expression Increases Breast Carcinoma Cell Responsiveness to the Malignancy-Enhancing Effects of Osteopontin11Grant 12078 from the Canadian Breast Cancer Research Initiative (AFC and ABT) ALA is supported by the HL Holmes Postdoctoral Award from the National Research Council of Canada. SAV is supported by a predoctoral award from the US Medical Research and Material Command Breast Cancer Research Program. This work was performed in partial fulfillment of the requirement for the M. Sc. degree ...." Molecular Cancer Research 1.11 (2003): 810-819.
Copy Download .nbib Format: MLA
… , NIH Cancer Biology Postdoctoral Fellowship T32 CA09676 (QP), Department of Defense Breast Cancer Research Program Postdoctoral Fellowship (QP), and …

postdoctoral

Merajver SD.
GSID: 026Pf6oj0JUJ
Q Pan, LW Bao, SD Merajver - Molecular Cancer Research, 2003 - AACR

Tetrathiomolybdate (TM), a specific copper chelator, has been shown to be a potent antiangiogenic and antimetastatic compound possibly through suppression of the NFκB signaling …

Cite
Pan, Q., Bao, L. W., & Merajver, S. D. (2003). Tetrathiomolybdate Inhibits Angiogenesis and Metastasis Through Suppression of the NFκB Signaling Cascade1 1 NIH grants R01CA77612 (SDM), P30CA46592, and M01-RR00042, Head and Neck SPORE P50CA97248, Susan G. Komen Breast Cancer Foundation, NIH Cancer Biology Postdoctoral Fellowship T32 CA09676 (QP), Department of Defense Breast Cancer Research Program Postdoctoral Fellowship (QP), and Tempting Tables Organization, Muskegon, MI. Molecular Cancer Research, 1(10), 701-706.
Pan, Quintin, Li Wei Bao, and Sofia D. Merajver. "Tetrathiomolybdate Inhibits Angiogenesis and Metastasis Through Suppression of the NFκB Signaling Cascade1 1 NIH grants R01CA77612 (SDM), P30CA46592, and M01-RR00042, Head and Neck SPORE P50CA97248, Susan G. Komen Breast Cancer Foundation, NIH Cancer Biology Postdoctoral Fellowship T32 CA09676 (QP), Department of Defense Breast Cancer Research Program Postdoctoral Fellowship (QP), and Tempting Tables Organization, Muskegon, MI." Molecular Cancer Research 1.10 (2003): 701-706.
Copy Download .nbib Format: MLA
Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

Breast cancer research and treatment

van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.
PMID: 27534944
Breast Cancer Res Treat. 2016 Sep;159(2):393. doi: 10.1007/s10549-016-3941-6.

No abstract available.

Cite
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, et al. Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016;159(2):393doi: 10.1007/s10549-016-3941-6.
van Ramshorst, M. S., van der Heiden-van der Loo, M., Dackus, G. M., Linn, S. C., & Sonke, G. S. (2016). Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast cancer research and treatment, 159(2), 393. https://doi.org/10.1007/s10549-016-3941-6
van Ramshorst, Mette S, et al. "Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer." Breast cancer research and treatment vol. 159,2 (2016): 393. doi: https://doi.org/10.1007/s10549-016-3941-6
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS. Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016 Sep;159(2):393. doi: 10.1007/s10549-016-3941-6. PMID: 27534944.
Copy Download .nbib Format: NLM
Detecting gene signature activation in breast cancer in an absolute, single-patient manner.

Breast cancer research : BCR

Paquet ER, Lesurf R, Tofigh A, Dumeaux V, Hallett MT.
PMID: 28327201
Breast Cancer Res. 2017 Mar 21;19(1):32. doi: 10.1186/s13058-017-0824-7.

BACKGROUND: The ability to reliably identify the state (activated, repressed, or latent) of any molecular process in the tumor of a patient from an individual whole-genome gene expression profile obtained from microarray or RNA sequencing (RNA-seq) promises important clinical...

Cite
Paquet ER, Lesurf R, Tofigh A, et al. Detecting gene signature activation in breast cancer in an absolute, single-patient manner. Breast Cancer Res. 2017;19(1):32doi: 10.1186/s13058-017-0824-7.
Paquet, E. R., Lesurf, R., Tofigh, A., Dumeaux, V., & Hallett, M. T. (2017). Detecting gene signature activation in breast cancer in an absolute, single-patient manner. Breast cancer research : BCR, 19(1), 32. https://doi.org/10.1186/s13058-017-0824-7
Paquet, E R, et al. "Detecting gene signature activation in breast cancer in an absolute, single-patient manner." Breast cancer research : BCR vol. 19,1 (2017): 32. doi: https://doi.org/10.1186/s13058-017-0824-7
Paquet ER, Lesurf R, Tofigh A, Dumeaux V, Hallett MT. Detecting gene signature activation in breast cancer in an absolute, single-patient manner. Breast Cancer Res. 2017 Mar 21;19(1):32. doi: 10.1186/s13058-017-0824-7. PMID: 28327201; PMCID: PMC5361722.
Copy Download .nbib Format: NLM
Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Breast cancer research : BCR

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.
PMID: 28183333
Breast Cancer Res. 2017 Feb 09;19(1):17. doi: 10.1186/s13058-017-0809-6.

No abstract available.

Cite
Hu Z, Mao JH, Curtis C, et al. Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res. 2017;19(1):17doi: 10.1186/s13058-017-0809-6.
Hu, Z., Mao, J. H., Curtis, C., Huang, G., Gu, S., Heiser, L., Lenburg, M. E., Korkola, J. E., Bayani, N., Samarajiwa, S., Seoane, J. A., Dane, M. A., Esch, A., Feiler, H. S., Wang, N. J., Hardwicke, M. A., Laquerre, S., Jackson, J., Wood, K. W., Weber, B., Spellman, P. T., Aparicio, S., Wooster, R., Caldas, C., & Gray, J. W. (2017). Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast cancer research : BCR, 19(1), 17. https://doi.org/10.1186/s13058-017-0809-6
Hu, Zhi, et al. "Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer." Breast cancer research : BCR vol. 19,1 (2017): 17. doi: https://doi.org/10.1186/s13058-017-0809-6
Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW. Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res. 2017 Feb 09;19(1):17. doi: 10.1186/s13058-017-0809-6. PMID: 28183333; PMCID: PMC5301377.
Copy Download .nbib Format: NLM
Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient.

Breast cancer research and treatment

Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ.
PMID: 27766452
Breast Cancer Res Treat. 2016 Dec;160(3):573. doi: 10.1007/s10549-016-4023-5.

No abstract available.

Cite
Churilla TM, Egleston BL, Murphy CT, et al. Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016;160(3):573doi: 10.1007/s10549-016-4023-5.
Churilla, T. M., Egleston, B. L., Murphy, C. T., Sigurdson, E. R., Hayes, S. B., Goldstein, L. J., & Bleicher, R. J. (2016). Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast cancer research and treatment, 160(3), 573. https://doi.org/10.1007/s10549-016-4023-5
Churilla, Thomas M, et al. "Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient." Breast cancer research and treatment vol. 160,3 (2016): 573. doi: https://doi.org/10.1007/s10549-016-4023-5
Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ. Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016 Dec;160(3):573. doi: 10.1007/s10549-016-4023-5. PMID: 27766452.
Copy Download .nbib Format: NLM
Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10.

Breast cancer research and treatment

[No authors listed]
PMID: 25929763
Breast Cancer Res Treat. 2015 Jun;151(2):479. doi: 10.1007/s10549-015-3399-y.

No abstract available.

Cite
Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10. Breast Cancer Res Treat. 2015;151(2):479doi: 10.1007/s10549-015-3399-y.
(2015). Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10. Breast cancer research and treatment, 151(2), 479. https://doi.org/10.1007/s10549-015-3399-y
"Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10." Breast cancer research and treatment vol. 151,2 (2015): 479. doi: https://doi.org/10.1007/s10549-015-3399-y
Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Breast Cancer Res Treat (2014) 147:203-10. Breast Cancer Res Treat. 2015 Jun;151(2):479. doi: 10.1007/s10549-015-3399-y. PMID: 25929763.
Copy Download .nbib Format: NLM
Investigation of the age trends in patients with breast cancer and different sizes of tumors in Breast Cancer Research Center of Isfahan University of Medical Sciences in 2001-2010.

Journal of education and health promotion

Tazhibi M, Dehkordi ZF, Babazadeh S, Tabatabaeian M, Rezaei P, Faghihi M.
PMID: 25013834
J Educ Health Promot. 2014 May 05;3:41. doi: 10.4103/2277-9531.131923. eCollection 2014.

BACKGROUND: Breast cancer is the most common cause of death in women in the age range of 35-55 years. Each year, one or two cases of breast cancer per 1000 women are diagnosed as new cases. Despite the serious...

Cite
Tazhibi M, Dehkordi ZF, Babazadeh S, et al. Investigation of the age trends in patients with breast cancer and different sizes of tumors in Breast Cancer Research Center of Isfahan University of Medical Sciences in 2001-2010. J Educ Health Promot. 2014;3:41doi: 10.4103/2277-9531.131923.
Tazhibi, M., Dehkordi, Z. F., Babazadeh, S., Tabatabaeian, M., Rezaei, P., & Faghihi, M. (2014). Investigation of the age trends in patients with breast cancer and different sizes of tumors in Breast Cancer Research Center of Isfahan University of Medical Sciences in 2001-2010. Journal of education and health promotion, 341. https://doi.org/10.4103/2277-9531.131923
Tazhibi, Mehdi, et al. "Investigation of the age trends in patients with breast cancer and different sizes of tumors in Breast Cancer Research Center of Isfahan University of Medical Sciences in 2001-2010." Journal of education and health promotion vol. 3 (2014): 41. doi: https://doi.org/10.4103/2277-9531.131923
Tazhibi M, Dehkordi ZF, Babazadeh S, Tabatabaeian M, Rezaei P, Faghihi M. Investigation of the age trends in patients with breast cancer and different sizes of tumors in Breast Cancer Research Center of Isfahan University of Medical Sciences in 2001-2010. J Educ Health Promot. 2014 May 05;3:41. doi: 10.4103/2277-9531.131923. eCollection 2014. PMID: 25013834; PMCID: PMC4089114.
Copy Download .nbib Format: NLM
Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.

Breast cancer research : BCR

Wu S, Weinstein SP, DeLeo MJ, Conant EF, Chen J, Domchek SM, Kontos D.
PMID: 26603870
Breast Cancer Res. 2015 Nov 24;17:144. doi: 10.1186/s13058-015-0651-7.

No abstract available.

Cite
Wu S, Weinstein SP, DeLeo MJ, et al. Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res. 2015;17:144doi: 10.1186/s13058-015-0651-7.
Wu, S., Weinstein, S. P., DeLeo, M. J., Conant, E. F., Chen, J., Domchek, S. M., & Kontos, D. (2015). Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast cancer research : BCR, 17144. https://doi.org/10.1186/s13058-015-0651-7
Wu, Shandong, et al. "Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers." Breast cancer research : BCR vol. 17 (2015): 144. doi: https://doi.org/10.1186/s13058-015-0651-7
Wu S, Weinstein SP, DeLeo MJ, Conant EF, Chen J, Domchek SM, Kontos D. Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res. 2015 Nov 24;17:144. doi: 10.1186/s13058-015-0651-7. PMID: 26603870; PMCID: PMC4659243.
Copy Download .nbib Format: NLM
Neutral sphingomyelinase and breast cancer research.

Journal of menopausal medicine

Hwang SY, Kim TH, Lee HH.
PMID: 26046034
J Menopausal Med. 2015 Apr;21(1):24-7. doi: 10.6118/jmm.2015.21.1.24. Epub 2015 Apr 27.

Our understanding of the functions of neutral sphingomyelinase (N-SMase) signaling has advanced over the past decade. In this review, we focus on the roles and regulation of N-SMase 1, N-SMase 2, N-SMase 3, an enzyme that generates the bioactive...

Cite
Hwang SY, Kim TH, Lee HH. Neutral sphingomyelinase and breast cancer research. J Menopausal Med. 2015;21(1):24-7doi: 10.6118/jmm.2015.21.1.24.
Hwang, S. Y., Kim, T. H., & Lee, H. H. (2015). Neutral sphingomyelinase and breast cancer research. Journal of menopausal medicine, 21(1), 24-7. https://doi.org/10.6118/jmm.2015.21.1.24
Hwang, Sun-Yong, et al. "Neutral sphingomyelinase and breast cancer research." Journal of menopausal medicine vol. 21,1 (2015): 24-7. doi: https://doi.org/10.6118/jmm.2015.21.1.24
Hwang SY, Kim TH, Lee HH. Neutral sphingomyelinase and breast cancer research. J Menopausal Med. 2015 Apr;21(1):24-7. doi: 10.6118/jmm.2015.21.1.24. Epub 2015 Apr 27. PMID: 26046034; PMCID: PMC4452810.
Copy Download .nbib Format: NLM
Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.

Breast cancer research and treatment

Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH, Zhu XF.
PMID: 26960710
Breast Cancer Res Treat. 2016 Apr;156(2):403-4. doi: 10.1007/s10549-016-3703-5.

Erratum to: Breast Cancer Res Treat (2012),134:549–560,DOI 10.1007/s10549-012-2080-y. In the original publication of the article, Fig. 5c was published incorrectly. The authors apologize for this error and the correct Fig. 5c is given below.

Cite
Tang J, Deng R, Luo RZ, et al. Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2016;156(2):403-4doi: 10.1007/s10549-016-3703-5.
Tang, J., Deng, R., Luo, R. Z., Shen, G. P., Cai, M. Y., Du, Z. M., Jiang, S., Yang, M. T., Fu, J. H., & Zhu, X. F. (2016). Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast cancer research and treatment, 156(2), 403-4. https://doi.org/10.1007/s10549-016-3703-5
Tang, Jun, et al. "Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients." Breast cancer research and treatment vol. 156,2 (2016): 403-4. doi: https://doi.org/10.1007/s10549-016-3703-5
Tang J, Deng R, Luo RZ, Shen GP, Cai MY, Du ZM, Jiang S, Yang MT, Fu JH, Zhu XF. Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat. 2016 Apr;156(2):403-4. doi: 10.1007/s10549-016-3703-5. PMID: 26960710.
Copy Download .nbib Format: NLM
Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways.

Breast cancer research and treatment

Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH.
PMID: 27412557
Breast Cancer Res Treat. 2016 Aug;158(3):605. doi: 10.1007/s10549-016-3905-x.

No abstract available.

Cite
Ahmad A, Wang Z, Kong D, et al. Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat. 2016;158(3):605doi: 10.1007/s10549-016-3905-x.
Ahmad, A., Wang, Z., Kong, D., Ali, R., Ali, S., Banerjee, S., & Sarkar, F. H. (2016). Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast cancer research and treatment, 158(3), 605. https://doi.org/10.1007/s10549-016-3905-x
Ahmad, Aamir, et al. "Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways." Breast cancer research and treatment vol. 158,3 (2016): 605. doi: https://doi.org/10.1007/s10549-016-3905-x
Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH. Retraction Note to: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways. Breast Cancer Res Treat. 2016 Aug;158(3):605. doi: 10.1007/s10549-016-3905-x. PMID: 27412557.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 557 entries